216
Views
14
CrossRef citations to date
0
Altmetric
Original Articles: Research

Suppression of STAT5A increases chemotherapeutic sensitivity in imatinib-resistant and imatinib-sensitive K562 cells

, , , , , , , & show all
Pages 1895-1901 | Received 18 May 2010, Accepted 06 Jul 2010, Published online: 20 Sep 2010
 

Abstract

STAT proteins are cytoplasmic transcription factors that are involved in the regulation of numerous cellular activities such as cell growth, differentiation, and survival. In this study, we aimed to identify the expression pattern of STAT genes in imatinib-sensitive and -resistant K562 cells, and further, to reveal the effects of STAT5A siRNA knockdown on cell growth and apoptosis induction. The XTT cell proliferation assay showed that both sensitive and resistant K562 cells were sensitized to imatinib upon transfection with STAT5A siRNA. Caspase-3 enzyme activity was increased significantly in both cells. These results may open up new opportunities to overcome chemotherapeutic resistance in leukemia.

Acknowledgement

We thank the staff of the Biotechnology and Bioengineering Center of the Izmir Institute of Technology for their help and technical support.

Declaration of interest: This work was supported by The Scientific and Technological Research Council of Turkey and by the Turkish Society of Hematology (TUBITAK 105S459 and THD 200-02/08, respectively, to BK).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.